 ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital Suvretta Holdings Corp III NASDAQ: DNAC in a deal valuing the combined entity at 2.64 billion. ProKidney first made waves in 2019, when it disclosed the 62 million acquisition of inRegen and raised 75 million to fund the deal and another takeover. 